Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Browse the world's most comprehensive archive of hedge fund manager letters. Access primary source research from leading institutional managers, sorted by reporting period.
Extreme correlation breakdowns between long and short equities alongside rising bond yields have prompted lower portfolio gross limits and a wider net short posture.
Full Quick Take
Extreme correlation breakdowns between long and short equities alongside rising bond yields have prompted lower portfolio gross limits and a wider net short posture.
Systematic equity selection leveraging broker sentiment and thematic AI tailwinds positions global portfolios to outpace macro valuation headwinds caused by rising real yields.
Full Quick Take
Systematic equity selection leveraging broker sentiment and thematic AI tailwinds positions global portfolios to outpace macro valuation headwinds caused by rising real yields.
Elevated inflation and technology valuation pressures require multi-asset diversification that balances artificial intelligence growth with selective intermediate sovereign debt and real commodity hedges.
Full Quick Take
Elevated inflation and technology valuation pressures require multi-asset diversification that balances artificial intelligence growth with selective intermediate sovereign debt and real commodity hedges.
Constructive on high-quality international small caps as valuation spreads compress, deploying capital into durable compounders in Japan including Sanrio, Milbon, and Japan Elevator Service while divesting challenged consumer franchises.
Full Quick Take
Constructive on high-quality international small caps as valuation spreads compress, deploying capital into durable compounders in Japan including Sanrio, Milbon, and Japan Elevator Service while divesting challenged consumer franchises.
Positioned defensively in high-quality consumer staples, healthcare, and insurance while underweighting high-multiple technology and discretionary retail, initiating new longs in Honeywell Aerospace and Equifax while divesting Target amid macro headwinds.
Full Quick Take
Positioned defensively in high-quality consumer staples, healthcare, and insurance while underweighting high-multiple technology and discretionary retail, initiating new longs in Honeywell Aerospace and Equifax while divesting Target amid macro headwinds.
Constructive on high-quality small-cap equities entering an earnings recovery cycle, selectively adding resilient healthcare in $LH while maintaining disciplined exposure to differentiated industrial and AI infrastructure compounders.
Full Quick Take
Constructive on high-quality small-cap equities entering an earnings recovery cycle, selectively adding resilient healthcare in $LH while maintaining disciplined exposure to differentiated industrial and AI infrastructure compounders.
Riverwater Partners Small Cap Strategy slightly underperformed the Russell 2000 in Q3 2026 due to sector allocation headwinds, while actively capitalizing on volatility to initiate high-visibility positions in Alliance Laundry, IRadimed, and Prestige Consumer Healthcare.
Full Quick Take
Riverwater Partners Small Cap Strategy slightly underperformed the Russell 2000 in Q3 2026 due to sector allocation headwinds, while actively capitalizing on volatility to initiate high-visibility positions in Alliance Laundry, IRadimed, and Prestige Consumer Healthcare.
Tactically trimming extended global technology ETF exposure to redeploy capital into oversold laggards across consumer staples, consumer discretionary, and utilities.
Full Quick Take
Tactically trimming extended global technology ETF exposure to redeploy capital into oversold laggards across consumer staples, consumer discretionary, and utilities.
Outperforming the Russell Midcap Growth Index's 5.84% decline through resilient selection in healthcare and communication services, while actively deploying into enterprise software on pullbacks.
Full Quick Take
Outperforming the Russell Midcap Growth Index's 5.84% decline through resilient selection in healthcare and communication services, while actively deploying into enterprise software on pullbacks.
Harris Oakmark leverages equity research to exploit technical supply indigestion in the corporate bond market, specifically lending to prime technology hyperscalers offering wide credit spreads despite negligible leverage and fortress cash flows.
Full Quick Take
Harris Oakmark leverages equity research to exploit technical supply indigestion in the corporate bond market, specifically lending to prime technology hyperscalers offering wide credit spreads despite negligible leverage and fortress cash flows.
Yet long-term fundamentals remain intact. The managers rebalanced capital from tech into materials, financials, consumer, and healthcare, viewing macro-driven volatility as an attractive setup to acquire high-visibility global businesses at discounted valuations.
Full Quick Take
Yet long-term fundamentals remain intact. The managers rebalanced capital from tech into materials, financials, consumer, and healthcare, viewing macro-driven volatility as an attractive setup to acquire high-visibility global businesses at discounted valuations.
In the third quarter of 2026, the ClearBridge Value Strategy delivered modest absolute returns but trailed the Russell 1000 Value Index due to an underweight stance in information technology and unfavorable stock selection in health care and tech.
Full Quick Take
In the third quarter of 2026, the ClearBridge Value Strategy delivered modest absolute returns but trailed the Russell 1000 Value Index due to an underweight stance in information technology and unfavorable stock selection in health care and tech.
Generating roughly 6% alpha against the TSX benchmark, led primarily by strong momentum in gold and precious metals mining coverage alongside selective diversified commercial turnarounds.
Full Quick Take
Generating roughly 6% alpha against the TSX benchmark, led primarily by strong momentum in gold and precious metals mining coverage alongside selective diversified commercial turnarounds.
Core holdings SpaceX, Filtronic, and ImmunityBio trade at compelling valuations: SpaceX at 23x earnings with 87% growth, Filtronic at 12x forward earnings at factory capacity, ImmunityBio addressing $43bn+ market.
Full Quick Take
Core holdings SpaceX, Filtronic, and ImmunityBio trade at compelling valuations: SpaceX at 23x earnings with 87% growth, Filtronic at 12x forward earnings at factory capacity, ImmunityBio addressing $43bn+ market.
Source Capital is pivoting away from the AI-driven market rally, reducing exposure to semiconductor and data center beneficiaries despite long-term bullish views on the technology.
Full Quick Take
Source Capital is pivoting away from the AI-driven market rally, reducing exposure to semiconductor and data center beneficiaries despite long-term bullish views on the technology.
ClearBridge All Cap Growth underperformed in Q2 as mega cap AI leadership resumed following tariff volatility, with the Strategy's diversified positioning creating a headwind versus the concentrated benchmark.
Full Quick Take
ClearBridge All Cap Growth underperformed in Q2 as mega cap AI leadership resumed following tariff volatility, with the Strategy's diversified positioning creating a headwind versus the concentrated benchmark.
Harbor Mid Cap Value outperformed in Q2 2026 through disciplined stock selection despite value lagging growth. AI infrastructure holdings TD Synnex, Arrow Electronics, and Hewlett Packard Enterprise surged 50-90% on semiconductor and data center demand.
Full Quick Take
Harbor Mid Cap Value outperformed in Q2 2026 through disciplined stock selection despite value lagging growth. AI infrastructure holdings TD Synnex, Arrow Electronics, and Hewlett Packard Enterprise surged 50-90% on semiconductor and data center demand.
Slightly trailing the S&P 500 on allocation effects. AI infrastructure drove market leadership, with the Fund adding semiconductor exposure through AMD and Micron positions.
Full Quick Take
Slightly trailing the S&P 500 on allocation effects. AI infrastructure drove market leadership, with the Fund adding semiconductor exposure through AMD and Micron positions.
Franklin Growth Opportunities Fund outperformed in Q2 2026 with a 20.9% return, led by Micron Technology's AI-driven surge and SpaceX's successful IPO.
Full Quick Take
Franklin Growth Opportunities Fund outperformed in Q2 2026 with a 20.9% return, led by Micron Technology's AI-driven surge and SpaceX's successful IPO.
CDT implements first-ever defensive hedging against technology sector, viewing AI as an unsustainable bubble with OpenAI burning -$21B annually and Meta wasting $125-145B with no results. Semiconductors at 19.7% of S&P 500 face earnings bust when capital discipline returns.
Full Quick Take
CDT implements first-ever defensive hedging against technology sector, viewing AI as an unsustainable bubble with OpenAI burning -$21B annually and Meta wasting $125-145B with no results. Semiconductors at 19.7% of S&P 500 face earnings bust when capital discipline returns.
FPA Crescent is executing a contrarian pivot away from AI-driven market leaders despite positive long-term technology views, scaling back semiconductor and data center exposure due to expanded valuations and advanced capital cycle stage.
Full Quick Take
FPA Crescent is executing a contrarian pivot away from AI-driven market leaders despite positive long-term technology views, scaling back semiconductor and data center exposure due to expanded valuations and advanced capital cycle stage.
Murata, Infineon, MediaTek and TSMC drove returns on multi-year AI infrastructure buildout. The fund deployed capital into biopharma recovery (Merck, Pharmaron), China automation (Inovance), and offshore wind turnaround (Orsted).
Full Quick Take
Murata, Infineon, MediaTek and TSMC drove returns on multi-year AI infrastructure buildout. The fund deployed capital into biopharma recovery (Merck, Pharmaron), China automation (Inovance), and offshore wind turnaround (Orsted).
Intel, Murata and MediaTek drove outperformance on AI infrastructure demand. The fund deployed capital aggressively, initiating thirteen positions including utilities, biotech tools and Chinese automation plays.
Full Quick Take
Intel, Murata and MediaTek drove outperformance on AI infrastructure demand. The fund deployed capital aggressively, initiating thirteen positions including utilities, biotech tools and Chinese automation plays.
Crushing the benchmark by 549 basis points on AI-driven semiconductor strength. The managers repositioned toward idiosyncratic growth stories, adding AI infrastructure plays while exiting disruption-vulnerable software names.
Full Quick Take
Crushing the benchmark by 549 basis points on AI-driven semiconductor strength. The managers repositioned toward idiosyncratic growth stories, adding AI infrastructure plays while exiting disruption-vulnerable software names.
Driven by European banks, Irish homebuilders, and a Capstone Copper recovery. The manager actively trimmed copper holdings on valuation concerns despite strong fundamentals, while initiating CSL at attractive multiples.
Full Quick Take
Driven by European banks, Irish homebuilders, and a Capstone Copper recovery. The manager actively trimmed copper holdings on valuation concerns despite strong fundamentals, while initiating CSL at attractive multiples.
Outperforming on strong semiconductor and biotech stock selection. The portfolio participated in AI infrastructure appreciation while maintaining discipline, with multiple semiconductor positions up over 100%.
Full Quick Take
Outperforming on strong semiconductor and biotech stock selection. The portfolio participated in AI infrastructure appreciation while maintaining discipline, with multiple semiconductor positions up over 100%.
Trailing its benchmark's 24.02% as factor headwinds from the risk-on rally overwhelmed positive stock selection. The portfolio's quality orientation and lower-beta positioning lagged as the market rewarded speculative, high-momentum names following geopolitical de-escalation.
Full Quick Take
Trailing its benchmark's 24.02% as factor headwinds from the risk-on rally overwhelmed positive stock selection. The portfolio's quality orientation and lower-beta positioning lagged as the market rewarded speculative, high-momentum names following geopolitical de-escalation.
Capitalizing on deeply discounted small-cap healthcare opportunities. The concentrated portfolio benefited from M&A activity, strong product launches at Liquidia and Electromed, and a 106% gain on Avanos acquisition.
Full Quick Take
Capitalizing on deeply discounted small-cap healthcare opportunities. The concentrated portfolio benefited from M&A activity, strong product launches at Liquidia and Electromed, and a 106% gain on Avanos acquisition.
Zeno argues Danaher is a high-quality compounder trading at a discount despite market-leading positions across Biotechnology, Diagnostics, and Life Sciences.
Full Quick Take
Zeno argues Danaher is a high-quality compounder trading at a discount despite market-leading positions across Biotechnology, Diagnostics, and Life Sciences.
Exiting Dave at peak valuations and Root after industry headwinds deepened, while maintaining conviction in Liquidia ahead of a catalyst and initiating positions in mispriced Celsius and Light & Wonder.
Full Quick Take
Exiting Dave at peak valuations and Root after industry headwinds deepened, while maintaining conviction in Liquidia ahead of a catalyst and initiating positions in mispriced Celsius and Light & Wonder.
Trailing the benchmark's 28.98% gain driven by historically narrow, speculative AI-related leadership. Biotechnology holdings delivered exceptional performance, contributing over 600 basis points, while defense and industrial holdings also performed well.
Full Quick Take
Trailing the benchmark's 28.98% gain driven by historically narrow, speculative AI-related leadership. Biotechnology holdings delivered exceptional performance, contributing over 600 basis points, while defense and industrial holdings also performed well.
Manager increasingly concerned AI capex boom is unsustainable, requiring unrealistic revenue growth with risk of violent crash given market concentration.
Full Quick Take
Manager increasingly concerned AI capex boom is unsustainable, requiring unrealistic revenue growth with risk of violent crash given market concentration.
Portfolio underperformed despite strong operational progress across holdings, with businesses now trading at lower valuations. MercadoLibre accelerated growth through reinvestment while Spotify expanded margins with AI monetization.
Full Quick Take
Portfolio underperformed despite strong operational progress across holdings, with businesses now trading at lower valuations. MercadoLibre accelerated growth through reinvestment while Spotify expanded margins with AI monetization.
Driven by Liquidia's fivefold gain as its drug launch succeeded spectacularly. The concentrated portfolio approach continues to work: largest positions consistently outperform.
Full Quick Take
Driven by Liquidia's fivefold gain as its drug launch succeeded spectacularly. The concentrated portfolio approach continues to work: largest positions consistently outperform.
Semiconductors surged 90% as AI infrastructure demand exploded. The manager trimmed AI exposure late quarter expecting consolidation but remains bullish on the second half given strong fundamentals and broadening market leadership.
Full Quick Take
Semiconductors surged 90% as AI infrastructure demand exploded. The manager trimmed AI exposure late quarter expecting consolidation but remains bullish on the second half given strong fundamentals and broadening market leadership.